Iambic Therapeutics files for IPO, secures partnerships with AbbVie and Jazz
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
What happened
Iambic Therapeutics filed for a U.S. IPO on September 21, 2026, planning to list on the Nasdaq. The company also announced multi-year collaborations with AbbVie and Jazz Pharmaceuticals. The agreement with AbbVie includes a $40 million upfront payment and potential development and sales-based milestones. Iambic Therapeutics received backing from Nvidia Corporation and Qatar Investment Authority.
Why it matters
The event links AI drug discovery technology, provided by Nvidia Corporation, with major pharmaceutical companies like AbbVie and Jazz Pharmaceuticals. The IPO and partnerships strengthen Iambic Therapeutics' financial position, which increases the value of its collaborations. The company plans to use IPO proceeds to advance three cancer drug candidates through clinical development.
Who's involved
- Jazz PharmaceuticalsPartnered with Iambic Therapeutics to test a drug candidate in HER2-positive breast cancer.
- AbbVieEntered a multi-year research collaboration with Iambic Therapeutics, utilizing its AI platform.
- Qatar Investment AuthorityProvided investment backing to Iambic Therapeutics.
- CitigroupIs underwriting the IPO offering for Iambic Therapeutics.
- NasdaqIs the intended exchange for Iambic Therapeutics' public listing.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Qatar Investment AuthoritySpeculative
Qatar Investment Authority could see an increase in the value of its investment in Iambic Therapeutics.
Keep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
-
AbbVie
pharmaceutical company
-
Qatar Investment Authority
Qatar's sovereign wealth fund founded in 2005
Nothing else this week.
Related events
- Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.